132 related articles for article (PubMed ID: 37774507)
1. Kinetic modelling of the P-glycoprotein mediated efflux with a large-scale matched molecular pair analysis.
Zhao H
Eur J Med Chem; 2023 Dec; 261():115830. PubMed ID: 37774507
[TBL] [Abstract][Full Text] [Related]
2. Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1).
Sharom FJ
Biochem Cell Biol; 2006 Dec; 84(6):979-92. PubMed ID: 17215884
[TBL] [Abstract][Full Text] [Related]
3. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
4. Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.
Dupuis ML; Ascione A; Palmisano L; Vella S; Cianfriglia M
BMC Pharmacol Toxicol; 2013 Sep; 14():47. PubMed ID: 24053678
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake.
de Graaf D; Sharma RC; Mechetner EB; Schimke RT; Roninson IB
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1238-42. PubMed ID: 8577747
[TBL] [Abstract][Full Text] [Related]
6. Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter.
Romsicki Y; Sharom FJ
Biochemistry; 2001 Jun; 40(23):6937-47. PubMed ID: 11389609
[TBL] [Abstract][Full Text] [Related]
7. Reconstitution and functional studies of hamster P-glycoprotein in giant liposomes.
Park S; Majd S
PLoS One; 2018; 13(6):e0199279. PubMed ID: 29912971
[TBL] [Abstract][Full Text] [Related]
8. Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates.
Kwon H; Lionberger RA; Yu LX
Mol Pharm; 2004; 1(6):455-65. PubMed ID: 16028357
[TBL] [Abstract][Full Text] [Related]
9. Molecular factors influencing the affinity of flavonoid compounds on P-glycoprotein efflux transporter.
Vázquez RN; Camargo AB; Marchevsky EJ; Luco JM
Curr Comput Aided Drug Des; 2014; 10(3):250-8. PubMed ID: 25756670
[TBL] [Abstract][Full Text] [Related]
10. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier.
Yu XY; Lin SG; Chen X; Zhou ZW; Liang J; Duan W; Chowbay B; Wen JY; Chan E; Cao J; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):365-78. PubMed ID: 17504224
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
[TBL] [Abstract][Full Text] [Related]
12. Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence.
Wang EJ; Casciano CN; Clement RP; Johnson WW
Biochim Biophys Acta; 2000 Aug; 1481(1):63-74. PubMed ID: 10962093
[TBL] [Abstract][Full Text] [Related]
13. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Webster LO; Barnaby RJ; Vitulli G; Bertolotti L; Read KD; Serabjit-Singh CJ
Drug Metab Dispos; 2004 Jul; 32(7):722-6. PubMed ID: 15205387
[TBL] [Abstract][Full Text] [Related]
14. Multiple transport-active binding sites are available for a single substrate on human P-glycoprotein (ABCB1).
Chufan EE; Kapoor K; Sim HM; Singh S; Talele TT; Durell SR; Ambudkar SV
PLoS One; 2013; 8(12):e82463. PubMed ID: 24349290
[TBL] [Abstract][Full Text] [Related]
15. Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.
Kuteykin-Teplyakov K; Luna-Tortós C; Ambroziak K; Löscher W
Br J Pharmacol; 2010 Jul; 160(6):1453-63. PubMed ID: 20590635
[TBL] [Abstract][Full Text] [Related]
16. Isolation of MDCK cells with low expression of
Bokulić A; Padovan J; Stupin-Polančec D; Milić A
Acta Pharm; 2022 Jun; 72(2):275-288. PubMed ID: 36651516
[TBL] [Abstract][Full Text] [Related]
17. Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).
Jansson PJ; Yamagishi T; Arvind A; Seebacher N; Gutierrez E; Stacy A; Maleki S; Sharp D; Sahni S; Richardson DR
J Biol Chem; 2015 Apr; 290(15):9588-603. PubMed ID: 25720491
[TBL] [Abstract][Full Text] [Related]
18. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.
Collett A; Tanianis-Hughes J; Hallifax D; Warhurst G
Pharm Res; 2004 May; 21(5):819-26. PubMed ID: 15180340
[TBL] [Abstract][Full Text] [Related]
19. The role of passive transbilayer drug movement in multidrug resistance and its modulation.
Eytan GD; Regev R; Oren G; Assaraf YG
J Biol Chem; 1996 May; 271(22):12897-902. PubMed ID: 8662680
[TBL] [Abstract][Full Text] [Related]
20. MDR1 P-glycoprotein reduces influx of substrates without affecting membrane potential.
Luker GD; Flagg TP; Sha Q; Luker KE; Pica CM; Nichols CG; Piwnica-Worms D
J Biol Chem; 2001 Dec; 276(52):49053-60. PubMed ID: 11598111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
